Exchange: NYSE·Updated 05:24 PM EDT
JNJ logo

JNJJohnson & Johnson

$258.52
$4.30
(1.63%)
Today
Closed $259.10
$0.58
(0.22%)
After Hours
EarningsJul 15
Mkt Cap$634.06B
Vol6.31M
News
all
press releases
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks
News Placeholder
More News
News Placeholder
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
Johnson & Johnson (JNJ) closed at $263.4 in the latest trading session, marking a -1.44% move from the prior day.
Zacks
News Placeholder
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
Zacks
News Placeholder
Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) approved the Dual Energy THERMOCOOL SMARTTOUCH SF Platform (DE STSF), an integrated catheter ablation solution that enables electrophysiologists to deliver both radiofrequency (RF) and pulsed field (PF...
Business Wire
News Placeholder
LQDA Stock Soars 129.7% YTD: Is There More Room for Growth?
Liquidia has surged 129.7% so far in 2026 as Yutrepia gains traction, driving strong sales, profitability and higher earnings estimates.
Zacks
News Placeholder
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?
Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.
Zacks
News Placeholder
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Zacks
News Placeholder
J&J's MedTech Segment Eyes Another Strong Quarter in Q2
JNJ's Q2 MedTech results will test whether cardiovascular, surgery and vision strength can offset ongoing China VBP headwinds and sustain growth.
Zacks
News Placeholder
Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?
ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.
Zacks
News Placeholder
Johnson & Johnson Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
JNJ will release its Q2 earnings on July 15, with analysts expecting earnings of $2.85 per share and revenue of $25.05 billion. Stock rose 3.6%.read more...
Benzinga
<
1
2
...
>

Advertisement|Remove ads.